Several studies have tried to identify novel diagnostic and prognostic biomarkers for the management of oral cancer patients, however, the currently available diagnostic strategies, mainly based on the evaluation of tumor biomarkers (CEA, CA19-9, CA125) or serum and salivary pro-inflammatory cytokines (IL-6, IL-8, etc.), often fail to diagnose correctly oral cancer lesions due to the low rates of sensitivity and specificity of these biomarkers [33,34,35]. This evidence concerns the gene CXCL8 and lip and oral cavity carcinoma.